Citations

Clear

3138 citation(s) found for "Smith, AM".

Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601
Pang, Herbert , Ye, C., Cirrincione, Constance, Fleishman, Stewart B., Ahles, Tim A. , Bressler, Linda R., Le‐Lindqwister, Nguyet, Loprinzi, Charles L. , Lavoie Smith, Ellen M , Paskett, Electra D. , Fadul, Camilo E. , Shapiro, Charles L.

Mayo Clinic

European Journal of Cancer Care | November 25, 2015 | Volume: 26 | Issue: 2 | Pages: e12421

10.1111/ecc.12421 | PMID 26603828 Get It

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Piccart, Martine , Holmes, Eileen , Baselga, José , Azambuja, Evandro de , Dueck, Amylou C. , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Armour, Alison, McCullough, Ann E. , Dolci, Stella, McFadden, Eleanor, Holmes, Andrew , Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong , Cosimo, Serena Di , Tjulandin, Sergei , Im, Young‐Hyuck , Huang, Chiun‐Sheng , Wolff, Antonio C. , Jackisch, Christian , Láng, István, Boyle, Frances , Gómez, Henry , Gelber, Richard D. , Perez, Edith A. , Piccart-Gebhart, Martine, de Azambuja, Evandro, Pritchard, Kathleen I. , Holmes, Andrew P, Di Cosimo, Serena, Harbeck, Nadia , Dièras, Véronique , Hillman, David W. , Untch, Michael , Smith, Ian , Xu, Binghe , Suter, Thomas, Dueck, A. C. , Zujewski, Jo Anne , Tonghua, Liu, Xu, Binghe , Suter, Thomas , Wolff, Antonio C , de Azambuja, Evandro , Huang, Chiun-Sheng

Mayo Clinic

Journal of Clinical Oncology | November 23, 2015 | Volume: 34 | Issue: 10 | Pages: 1034-1042

10.1200/jco.2015.62.1797 | PMID 26598744 Get It

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed human epidermal growth factor 2–positive early breast cancer were randomly assigned to 1 year of adjuvant therapy with T, L, their sequence (T→L), or their combination (L+T). The primary end point was disease-free survival (DFS), with 850 events required for 80% power to detect a hazard ratio (HR) of 0.8 for L+T versus T. Results Between June 2007 and July 2011, 8,381 patients were enrolled. In 2011, due to futility to demonstrate noninferiority of L versus T, the L arm was closed, and patients free of disease were offered adjuvant T. A protocol modification required P ≤ .025 for the two remaining pairwise comparisons. At a protocol-specified analysis with a median follow-up of 4.5 years, a 16% reduction in the DFS hazard rate was observed with L+T compared with T (555 DFS events; HR, 0.84; 97.5% CI, 0.70 to 1.02; P = .048), and a 4% reduction was observed with T→L compared with T (HR, 0.96; 97.5% CI, 0.80 to 1.15; P = .61). L-treated patients experienced more diarrhea, cutaneous rash, and hepatic toxicity compared with T-treated patients. The incidence of cardiac toxicity was low in all treatment arms. Conclusion Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care.
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, Thomas , Sun, Zhuoxin , Ketterling, Rhett P. , Zeidan, Amer M. , Greenberg, Peter L. , Herman, James G. , Malick, Lisa, Paietta, Elisabeth , Czader, Magdalena , Figueroa, María E. , Gabrilove, Janice , Tallman, Martin S. , Litzow, Mark R. , Gore, Steven D. , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Juckett, Mark , Smith, Mitchell R. , Erba, Harry Paul , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Prebet, Thomas , Ketterling, Rhett P , Zeidan, Amer M

Mayo Clinic

British Journal of Haematology | November 18, 2015 | Volume: 172 | Issue: 3 | Pages: 384-391

10.1111/bjh.13832 | PMID 26577691 Get It

AbstractTherapy‐related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m2/d) +/− the histone deacetylase inhibitor entinostat (4 mg/m2/d PO day‐3 and day‐10). A total of 47 patients [29 therapy‐related myelosyspastic syndrome (t‐MDS) and 18 therapy‐related acute myeloid leukaemia (t‐AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0·008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.
A Spectrum of Views on Clinical Mass Spectrometry
Annesley, Thomas M, Diamandis, Eleftherios P. , Bachmann, Lorin M, Hart, Bradley R. , Javahery, Reza, Hanash, Samir , Singh, Ravinder , Smith, Richard , Diamandis, Eleftherios

Mayo Clinic

Clinical Chemistry | November 10, 2015 | Volume: 62 | Issue: 1 | Pages: 30-36

10.1373/clinchem.2015.250258 | PMID 26553793 Get It

Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosis
Gelbard, Alexander , Donovan, Donald T., Ongkasuwan, Julina , Nouraei, S.A.R. , Sandhu, Guri, Benninger, Michael S. , Bryson, Paul C. , Lorenz, Robert R. , Gadkaree, Shekhar K. , Edell, Eric S. , Ekbom, Dale C. , Kasperbauer, Jan L. , Maldonado, Fabien , Schindler, Joshua S. , Smith, Marshall E. , Daniero, James J. , Garrett, C. Gaelyn , Netterville, James L. , Rickman, Otis B. , Sinard, Robert J. , Wootten, Christopher T. , Francis, David O. , Tierney, William S. , Hillel, Alexander T. , Lott, David G. , Ongkasuwan, Julian , Gelbard, Alexander

Mayo Clinic

The Laryngoscope | November 4, 2015 | Volume: 126 | Issue: 6 | Pages: 1390-1396

10.1002/lary.25708 | PMID 26536285 Get It

Objectives/Hypothesis Idiopathic subglottic stenosis (iSGS) is a rare and potentially life‐threatening disease marked by recurrent and progressive airway obstruction frequently requiring repeated surgery to stabilize the airway. Unknown etiology and low disease prevalence have limited the ability to characterize the natural history of iSGS and resulted in variability in surgical management. It is uncertain how this variation relates to clinical outcomes. Study Design Medical record abstraction. Methods Utilizing an international, multi‐institutional collaborative, we collected retrospective data on patient characteristics, treatment, and clinical outcomes. We investigated variation between and within open and endoscopic treatment approaches and assessed therapeutic outcomes; specifically, disease recurrence and need for tracheostomy at last follow‐up. Results Strikingly, 479 iSGS patients across 10 participating centers were nearly exclusively female (98%, 95% confidence interval [CI], 96.1–99.6), Caucasian (95%, 95% CI, 92.2–98.8), and otherwise healthy (mean age‐adjusted Charlson Comorbidity Index 1.5; 95% CI, 1.44–1.69). The patients presented at a mean age of 50 years (95% CI, 48.8–51.1). A total of 80.2% were managed endoscopically, whereas 19.8% underwent open reconstruction. Endoscopic surgery had a significantly higher rate of disease recurrence than the open approach (chi 2 = 4.09, P = 0.043). Tracheostomy was avoided in 97% of patients irrespective of surgical approach (95% CI, 94.5–99.8). Interestingly, there were outliers in rates of disease recurrence between centers using similar treatment approaches. Conclusion Idiopathic subglottic stenosis patients are surprisingly homogeneous. The heterogeneity of treatment approaches and the observed outliers in disease recurrence rates between centers raises the potential for improved clinical outcomes through a detailed understanding of the processes of care. Level of Evidence 4. Laryngoscope , 126:1390–1396, 2016
A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution
Walsh, Kyle M. , Smith, Adam J. de , Hansen, Helen M. , Smirnov, Ivan, Gonseth, Semira , Endicott, Alyson , Xiao, Jianqiao, Rice, Terri, Fu, Cecilia, McCoy, Lucie , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Wrensch, Margaret , Metayer, Catherine , Wiemels, Joseph L. , Lachance, Daniel Honore , Wiencke, John K. , Ma, Xiaomei

Mayo Clinic

Cancer Research | November 2, 2015 | Volume: 75 | Issue: 22 | Pages: 4884-4894

10.1158/0008-5472.can-15-1105 | PMID 26527286 Get It

Abstract Genome-wide association studies (GWAS) have identified SNPs in six genes that are associated with childhood acute lymphoblastic leukemia (ALL). A lead SNP was found to occur on chromosome 9p21.3, a region that is deleted in 30% of childhood ALLs, suggesting the presence of causal polymorphisms linked to ALL risk. We used SNP genotyping and imputation-based fine-mapping of a multiethnic ALL case–control population (Ncases = 1,464, Ncontrols = 3,279) to identify variants of large effect within 9p21.3. We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 × 10−9) and Hispanic children (OR, 2.77; P = 3.78 × 10−4). Moreover, of 17 patients whose tumors displayed allelic imbalance at CDKN2A, 14 preferentially retained the risk allele and lost the protective allele (PBinomial = 0.006), suggesting that the risk allele provides a selective advantage during tumor growth. Notably, the CDKN2A variant was not significantly associated with melanoma, glioblastoma, or pancreatic cancer risk, implying that this polymorphism specifically confers ALL risk but not general cancer risk. Taken together, our findings demonstrate that coding polymorphisms of large effect can underlie GWAS “hits” and that inherited polymorphisms may undergo directional selection during clonal expansion of tumors. Cancer Res; 75(22); 4884–94. ©2015 AACR.
Identification and Functional Characterization of a Novel CACNA1C -Mediated Cardiac Disorder Characterized by Prolonged QT Intervals With Hypertrophic Cardiomyopathy, Congenital Heart Defects, and Sudden Cardi
Boczek, Nicole J. , Ye, Dan , Jin, Fang , Tester, David J. , Kelcher, April M. Huseby , Bos, J. Martijn , Johnson, Aaron J. , Kanter, Ronald J. , Ackerman, Michael J. , Huseby, April, Kanter, Ronald, Johnson, Aaron J. , Kelcher, April M H , Bos, Johan M

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 20, 2015 | Volume: 8 | Issue: 5 | Pages: 1122-1132

10.1161/circep.115.002745 | PMID 26253506 Get It

Background— A portion of sudden cardiac deaths can be attributed to structural heart diseases, such as hypertrophic cardiomyopathy (HCM) or cardiac channelopathies such as long-QT syndrome (LQTS); however, the underlying molecular mechanisms are distinct. Here, we identify a novel CACNA1C missense mutation with mixed loss-of-function/gain-of-function responsible for a complex phenotype of LQTS, HCM, sudden cardiac death, and congenital heart defects. Methods and Results— Whole exome sequencing in combination with Ingenuity variant analysis was completed on 3 affected individuals and 1 unaffected individual from a large pedigree with concomitant LQTS, HCM, and congenital heart defects and identified a novel CACNA1C mutation, p.Arg518Cys, as the most likely candidate mutation. Mutational analysis of exon 12 of CACNA1C was completed on 5 additional patients with a similar phenotype of LQTS plus a personal or family history of HCM-like phenotypes and identified 2 additional pedigrees with mutations at the same position, p.Arg518Cys/His. Whole cell patch clamp technique was used to assess the electrophysiological effects of the identified mutations in Ca V 1.2 and revealed a complex phenotype, including loss of current density and inactivation in combination with increased window and late current. Conclusions— Through whole exome sequencing and expanded cohort screening, we identified a novel genetic substrate p.Arg518Cys/His-CACNA1C, in patients with a complex phenotype including LQTS, HCM, and congenital heart defects annotated as cardiac-only Timothy syndrome. Our electrophysiological studies, identification of mutations at the same amino acid position in multiple pedigrees, and cosegregation with disease in these pedigrees provide evidence that p.Arg518Cys/His is the pathogenic substrate for the observed phenotype.
A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus
Chowdhary, Vaidehi , Dai, Chao , Tilahun, Ashenafi Y. , Hanson, Julie A., Smart, Michele, Grande, Joseph P. , Rajagopalan, Govindarajan , Fu, Shu Man , David, Chella S., Chowdhary, Vaidehi R, Smart, Michele K

Mayo Clinic

The Journal of Immunology | October 17, 2015 | Volume: 195 | Issue: 10 | Pages: 4660-4667

10.4049/jimmunol.1501073 | PMID 26475924 Get It

Abstract MHC, especially HLA-DR3 and HLA-DR2, is one of the most important genetic susceptibility regions for systemic lupus erythematosus. Human studies to understand the role of specific HLA alleles in disease pathogenesis have been hampered by the presence of strong linkage disequilibrium in this region. To overcome this, we produced transgenic mice expressing HLA-DR3 (DRβ1*0301) and devoid of endogenous class II (both I-A and I-E genes, AE0) on a lupus-prone NZM2328 background (NZM2328.DR3+AE0). Both NZM2328 and NZM2328.DR3+AE0 mice developed anti-dsDNA and glomerulonephritis, but anti-dsDNA titers were higher in the latter. Although kidney histological scores were similar in NZM2328 and NZM2328.DR3+AE0 mice (7.2 ± 4.3 and 8.6 ± 5.7, respectively, p = 0.48), the onset of severe proteinuria occurred earlier in NZM2328.DR3+AE0 mice compared with NZM2328 mice (median, 5 and 9 mo respectively, p < 0.001). Periarterial lymphoid aggregates, classic wire loop lesions, and occasional crescents were seen only in kidneys from NZM2328.DR3+AE0 mice. Interestingly, NZM2328.DR3+AE0 mice, but not NZM2328 mice, spontaneously developed anti-Smith (Sm) Abs. The anti-Sm Abs were seen in NZM2328.DR3+AE0 mice that were completely devoid of endogenous class II (AE-/-) but not in mice homozygous (AE+/+) or heterozygous (AE+/−) for endogenous MHC class II. It appears that only HLA-DR3 molecules can preferentially select SmD-reactive CD4+ T cells for generation of the spontaneous anti-Sm immune response. Thus, our mouse model unravels a critical role for HLA-DR3 in generating an autoimmune response to SmD and lupus nephritis in the NZM2328 background.
To clamp or not to clamp? Long‐term functional outcomes for elective off‐clamp laparoscopic partial nephrectomy
Shah, Paras , George, Arvin K. , Moreira, Daniel M. , Alom, Manaf, Okhunov, Zhamshid , Salami, Simpa S. , Waingankar, Nikhil , Schwartz, Michael J. , Vira, Manish , Richstone, Lee, Kavoussi, Louis R., Salami, Simpa S

Mayo Clinic

BJU International | September 8, 2015 | Volume: 117 | Issue: 2 | Pages: 293-299

10.1111/bju.13309 | PMID 26348366 Get It

Objective To evaluate whether elective off‐clamp laparoscopic partial nephrectomy ( LPN ) affords long‐term renal functional benefit compared with the on‐clamp approach. Patients and Methods This is a retrospective review of patients who underwent elective LPN between 2006 and 2011. Patients were followed longitudinally for up to 5 years. In all, 315 patients with radiographic evidence of a solitary renal mass and normal‐appearing contralateral kidney underwent elective LPN ; 209 were performed on‐clamp vs 106 off‐clamp. One patient who required conversion from LPN to open PN was excluded from the study. Additionally, four patients in the on‐clamp cohort who underwent subsequent radical nephrectomy for local‐regional recurrence were excluded from longitudinal functional evaluation after their procedure. The primary objective was to evaluate differences in postoperative estimated glomerular filtration rate ( eGFR ) between hilar clamping groups. Subgroup analyses were performed for patients with clamp times >30 min and those with baseline renal insufficiency ( eGFR <60 mL/min/1.73m 2 ). Risk of developing worsened or new‐onset renal insufficiency was also compared. Results The mean preoperative eGFR was similar between the on‐clamp and off‐clamp cohorts (80.7 vs 84.1 mL/min/1.73m 2 , P > 0.05). Univariable and multivariable analyses did not show significant differences in postoperative eGFR between both groups among all‐comers, those with clamp times >30 min, and patients with baseline renal insufficiency. Risk of chronic kidney disease was not diminished by the off‐clamp approach with up to 5 years of follow‐up. Conclusions Progressive recovery of renal function after hilar clamping in the elective setting eclipses short‐term functional benefit achieved with off‐clamp LPN by 6 months; there was no significant difference in eGFR or the percentage incidence of chronic kidney disease between the on‐clamp and off‐clamp cohorts with up to 5 years follow‐up. As such, eliminating transient ischaemia during elective LPN does not confer clinical benefit.